High Through-put Discovery of Malaria Drug Targets

描述(申请人提供)：新发和再发传染病 疾病是导致疼痛、痛苦和 发展中国家的贫困问题。对于一般的寄生虫病，疫苗 都不存在，而且都不太可能对 可预见的未来。在疟疾的情况下，没有疫苗即将出现 以及对常用治疗药物的抗药性日益普遍， 显然，有必要开发更多的抗疟疾药物。然而， 包括开发成本增加在内的几个因素导致了 大多数制药公司退出了新的开发 抗疟疾疗法。本文件中描述的研究和开发 提案利用一种新的具有成本效益的方法来达到抗疟疾药物的目标 发现号。我们将使用比较的方法来确定潜在的治疗方法 恶性疟原虫、弓形虫和柔嫩艾美耳球虫的共同靶标。 这项工作将构成未来第二阶段应用程序的基础，该应用程序将使用 在此开发的试剂用于鉴定广谱apicplexan特异性 抑制剂化合物。

DESCRIPTION (Provided by applicant): Emerging and re-emerging infectious diseases are some of the most important contributors to pain, suffering and poverty in the developing world. For parasitic diseases in general, vaccines are nonexistent and none are likely to have a significant impact in the foreseeable future. In the case of malaria, without a vaccine on the horizon and an increasing prevalence of resistance to commonly used therapeutic drugs, the need for additional anti-malarial drug development is obvious. However, several factors, including increased cost of development, have lead to the retreat of most pharmaceutical companies from the development of new anti-malarial therapeutics. The research and development described in this proposal utilizes a new cost effective approach to anti-malarial drug target discovery. We will use a comparative approach to identify potential therapeutic targets common to Plasmodium falciparum, Toxoplasma gondii and Eimeria tenella. This work will form the basis for a future phase II application, which will use the reagents developed here to identify broad spectrum apicomplexan specific inhibitor compounds.